MTOR and systemic lupus erythematosus: Although drugs that target mTOR, AMPK, and glycolytic systems such as sirolimus, rapamycin, and metformin have shown some efficacy and tolerability in clinical trials in patients with SLE, they have not led to major developments in therapeutic approaches. A better understanding of intrinsic immunometabolism mechanisms including those for B cells and other immune cells, is needed, and may aid the development of novel treatments for SLE.